Bristol Tax Reporting (Correction)
This article was originally published in The Pink Sheet Daily
Bristol-Myers Squibb's incoming tax reporting controls remain a "reportable condition," according to the company's auditors, PricewaterhouseCoopers.In a story on Bristol's latest earnings restatement, "The Pink Sheet" DAILY incorrectly reported that the tax controls are considered a "material weakness." Bristol has resolved both "material weaknesses" identified by PwC a year ago (1"The Pink Sheet" DAILY, March 15, 2004)
You may also be interested in...
The company adjusts reported 2003 revenues by about $200 mil. Although impact of Bristol's second restatement is smaller than the first, tax issues and treatment of "grants" as advertising expenses could hint at deeper issues.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.